Impact of comorbidities in elderly and frail patients and response to biological therapy in psoriasis
Experimental Dermatology · 2023
DOI: 10.1111/exd.14822 ↗At a glance
Leserbrief in Experimental Dermatology, 2023. Written by F Rosset and 4 co-authors. Institution: Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy. Major MEDLINE topics: Psoriasis, Biological Products. Cited 8 times so far (Crossref); 7 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Dear Editor., Psoriasis is a chronic inflammatory disease commonly seen in older patients: its prevalence in over65 is estimated 0.14%– 1.99%.1 Moderatetosevere disease has indication to systemic therapy2 which can be challenging in older subjects due to the common presence of frailty and comorbidities. Data regarding biological therapies in the elderly and frail are lacking.3 Due to the high rate of comorbidities in this age group, these patients are often excluded from clinical trials based on their inclusion and exclusion criteria. For this reason, most of the available data regarding the treatment with biological agents in elderly patients came from daily practice, hence from reallife studies, case reports, and case series.4 Herein, we present a case series of elderly psoriatic patients treated with biological therapy, evaluating the impact of different comorbidities in a reallife clinical setting of a tertiary level university hospital. Of 1600 patients under treatment with antiIL23 (tildrakizumab, guselkumab and risankizumab) or antiIL17 (secukinumab, ixekizumab and brodalumab) agents for psoriasis treated from 2019 until 2022, a total of 280 were over 65 years. In this analysis, we clustered patients into two groups: patients who reported at least one comorbidity at the time of the diagnosis (219, 78.21%) and those who denied comorbidities (61, 21.79%). Comorbidities included chronic diseases (cardiological, haematological, gastroenterological, neurological, infectious disease, endocrinological, nephrourological, psychiatric and ophthalmological). We compared the two groups for different variables: sex, BMI, difficulttotreat locations of psoriasis, arthropathy, naivety for biological drugs at the start of treatment, type of biologic, Psoriasis Area Severity Index (PASI) at different time points (T0, 16 weeks, 28 weeks and 52 weeks) as well as PASI100, PASI90 and PASI
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
ORCID profiles: F Rosset, L Mastorino, P Quaglino, S Ribero
Cite
APA
Rosset, F., Mastorino, L., Dapavo, P., Quaglino, P., & Ribero, S. (2023). Impact of comorbidities in elderly and frail patients and response to biological therapy in psoriasis. Experimental Dermatology. https://doi.org/10.1111/exd.14822
Vancouver
Rosset F, Mastorino L, Dapavo P, Quaglino P, Ribero S. Impact of comorbidities in elderly and frail patients and response to biological therapy in psoriasis. Experimental Dermatology. 2023. doi:10.1111/exd.14822
BibTeX
@article{Rosset2023,
author = {Rosset, F and Mastorino, L and Dapavo, P and Quaglino, P and Ribero, S},
title = {Impact of comorbidities in elderly and frail patients and response to biological therapy in psoriasis},
journal = {Experimental Dermatology},
year = {2023},
doi = {10.1111/exd.14822}
}
EUVIMED